The effects of Chinese proprietary medicine and vaccination on patients with COVID-19: a retrospective study in Macao

• Main Authors: Hui Mo (Author), Man-Fei Zhou (Author), Edmundo Patricio Lopes Lao (Author), Ka-Kei Chan (Author), On-Na Lai (Author), Man-In Ho (Author), Kin-Wa Wong (Author), Ka-Meng Ho (Author), Kin-Tim Sio (Author), Keng-Lam Fong (Author), Yong-Hua Zhao (Author), Seng-Ip Cheang (Author), Iek-Long Lo (Author)
• Format: Book
• Published: BMC, 2024-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background COVID-19 is continuing to ravage globally and has resulted in a huge health and financial burden. Chinese proprietary medicines, such as Lianhua Qingwen (LHQW) and Huoxiang Zhengqi (HXZQ) capsules, have been recommended for non-high-risk patients with COVID-19 in China. Based on...